Lamivudine-Zidovudine-Nevirapine 150mg-300mg-200mg

Lamivudine-Zidovudine-Nevirapine 150mg-300mg-200mg – Quick Overview

Lamivudine-Zidovudine-Nevirapine 150mg-300mg-200mg is a fixed-dose combination antiretroviral tablet used to treat HIV-1 infection in adults. It contains three medicines that work together to slow HIV replication in the body. This combination is prescription-only, carries important safety warnings including a risk of serious liver toxicity, and requires close medical supervision.

Medical Supervision & Regulatory Status

This fixed-dose combination has received FDA approval and is available only by prescription, including through tentative approval pathways supporting global HIV treatment programs. Medical supervision is required due to the risk of serious liver toxicity, skin reactions, and other significant safety concerns associated with its components.

Clinical Context

HIV-1 infection progressively weakens the immune system by attacking CD4 cells, and if left untreated, it can lead to opportunistic infections and advanced immunodeficiency (AIDS). Long-term, consistent antiretroviral therapy is essential to suppress viral replication and preserve immune function.

Combining medicines from different antiretroviral classes is a core treatment strategy because it attacks the virus at multiple points in its replication cycle, reducing the chance of drug resistance developing compared to using a single agent alone.

This triple combination fits into therapy as a complete three-drug antiretroviral regimen in one tablet, simplifying dosing for adults with HIV-1 infection who are appropriate candidates for this specific drug combination based on their treatment history and lab values.

How Lamivudine-Zidovudine-Nevirapine Works

Lamivudine and zidovudine belong to the nucleoside reverse transcriptase inhibitor (NRTI) class, while nevirapine belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.

In simple terms, lamivudine and zidovudine work by getting incorporated into the virus’s genetic material during replication, causing early termination of viral DNA production, while nevirapine directly blocks the reverse transcriptase enzyme HIV needs to convert its RNA into DNA.

By attacking the same enzyme through two different mechanisms, this three-drug combination provides more effective and durable suppression of HIV replication than any single component alone, helping preserve immune function over time.

What is Lamivudine-Zidovudine-Nevirapine 150mg-300mg-200mg?

Uses / Indications

• HIV-1 infection in adults: Used as part of combination antiretroviral therapy to suppress viral replication and support immune function.

This combination is a fixed-dose tablet and cannot be dose-adjusted; it is not recommended in patients weighing less than 35 kg, those with creatinine clearance less than 50 mL/min, or those with hepatic impairment.

How to Use / Dosage

Treatment typically begins with a 14-day lead-in period of nevirapine dosed once daily (often using a separate nevirapine-only tablet) before switching to the fixed-dose combination twice daily, as this lead-in has been shown to reduce the risk of rash. It can be taken with or without food, with a full glass of water. Because this is a fixed-dose tablet, individual components cannot be adjusted, so dosing must be determined carefully by a physician. If a dose is missed, take it as soon as remembered, unless it is almost time for the next dose, in which case skip the missed dose — do not double up. Do not stop this medication without consulting your doctor, as interruptions can affect viral suppression and increase resistance risk.

Side Effects

Most people tolerate this combination with some side effects that should be discussed with a doctor. Common effects may include nausea, headache, fatigue, and skin rash, which is the most frequently reported reaction to the nevirapine component. Serious effects, though less common, may include severe liver toxicity (sometimes fatal), severe skin reactions, lactic acidosis with liver enlargement, and bone marrow suppression from the zidovudine component.

Emergency Warning Signs — Seek immediate medical care if you experience:

• Rash accompanied by fever, blistering, mouth sores, or eye irritation
• Yellowing of the skin or eyes (jaundice)
• Severe abdominal pain, nausea, or vomiting
• Unusual tiredness, muscle pain, or difficulty breathing (possible lactic acidosis)
• Signs of severe anemia (extreme fatigue, pale skin, rapid heartbeat)
• Unexplained bruising or bleeding
• Severe skin blistering or peeling

Warnings & Precautions

This combination carries a significant warning: fatal and non-fatal liver toxicity has been reported with nevirapine, particularly during the first weeks of treatment; therapy must be discontinued immediately if clinical hepatitis, transaminase elevations with rash, or other systemic symptoms occur, and it should not be restarted after such an event. It is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). Drug interactions are significant with medications affecting liver enzymes, particularly CYP3A4 inducers or inhibitors, given nevirapine’s metabolism, as well as interferon and ribavirin, which can worsen hepatic decompensation risk in HIV/HCV co-infected patients. Use during pregnancy should be discussed with a physician, as treatment decisions depend on the clinical situation, and breastfeeding is not recommended while taking this medication due to the risk of HIV transmission and infant drug exposure. Special populations, including patients with hepatitis B or C co-infection, kidney impairment, or a history of skin reactions to any component, require closer monitoring. Regular monitoring of liver function tests, particularly during the first 18 weeks of treatment, along with complete blood counts, is generally recommended during therapy.

Who Should Not Use This Medication

• People with moderate to severe hepatic impairment (Child-Pugh Class B or C)
• Individuals with a known hypersensitivity to lamivudine, zidovudine, or nevirapine
• Patients weighing less than 35 kg, due to the fixed-dose formulation
• Anyone with creatinine clearance less than 50 mL/min, without physician-directed dose management
• Breastfeeding mothers, due to HIV transmission and infant safety risk
• Patients who previously discontinued nevirapine due to severe liver or skin reactions

Storage Instructions

Store Lamivudine-Zidovudine-Nevirapine tablets at room temperature, away from excess heat and moisture. Keep the container tightly closed and protect from direct light. Keep out of reach of children and pets, and dispose of unused or expired medication appropriately rather than in household trash.

Frequently Asked Questions

What is the cost of Lamivudine-Zidovudine-Nevirapine without insurance?

The cost without insurance depends on the seller, brand availability, and pack size, and may also vary by location and available discounts. Generic versions are often more affordable, and assistance programs may reduce out-of-pocket cost.

How can I order Lamivudine-Zidovudine-Nevirapine online?

A valid prescription is required to order this medication. Typically, you upload a prescription or have your doctor send it directly, then order from a licensed pharmacy for home delivery. Always verify the pharmacy is properly licensed before ordering.

Is Lamivudine-Zidovudine-Nevirapine available over the counter?

No, it is not available over the counter in the United States or most other countries. Regulations may vary by region, but medical supervision is required due to its serious liver toxicity risk.

Does Lamivudine-Zidovudine-Nevirapine require a prescription?

Yes, a prescription is required. This ensures proper evaluation of liver and kidney function before starting, along with ongoing monitoring for safety.

How long does it take to work?

Viral suppression typically develops over several weeks to months of consistent use, with regular viral load testing used to monitor treatment response over time.

Can I stop taking this medication suddenly?

No, stopping suddenly without medical advice can lead to loss of viral suppression and increased risk of drug resistance. Any changes to your regimen should be guided by your doctor.

Does this medication interact with other drugs?

Yes, it can interact with medications affecting liver enzyme activity, interferon, ribavirin, and other drugs metabolized similarly. Always tell your doctor about all medications and supplements you take before starting therapy.

Resources

• MedlinePlus – Nevirapine: https://medlineplus.gov/druginfo/meds/a601049.html
• FDA – Lamivudine, Nevirapine, and Zidovudine Tablets Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205626s000lbl.pdf
• DailyMed (NIH) – Lamivudine/Zidovudine/Nevirapine Label: https://dailymed.nlm.nih.gov

References

1. FDA – Lamivudine, Nevirapine, and Zidovudine Tablets Full Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205626s000lbl.pdf
2. FDA (PEPFAR-supported approval) – Lamivudine/Nevirapine/Zidovudine Tablets Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/022464PI.pdf
3. MedlinePlus – Nevirapine: https://medlineplus.gov/druginfo/meds/a601049.html

Medical Disclaimer:

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified specialist or physician before using Lamivudine-Zidovudine-Nevirapine.